CRISM Therapeutics (LSE:CRTX) has begun recruiting patients for its Phase 2 trial in glioblastoma, marking a significant step for the clinical-stage drug delivery company. In its interim results published on 21 September 2026, the company said recruitment had started on 27 August 2026 at its first trial site and that dosing of the first patient was expected shortly.
What the company does
CRISM Therapeutics is a UK-focused clinical-stage company developing ChemoSeed, an implantable and biodegradable platform designed to deliver chemotherapy directly to tumours in a localised and sustained way. Its lead candidate is irinotecan-ChemoSeed, which is intended to be implanted during surgery for glioblastoma, an aggressive form of brain cancer. The company also has a docetaxel-ChemoSeed programme for prostate cancer in preclinical development. Registered in the British Virgin Islands, CRISM was admitted to AIM in May 2024 and is a constituent of the FTSE AIM All Share Index.
Latest developments
The Phase 2 study is described as a registration-grade, open-label trial in resectable glioblastoma. Part 1 involves dose escalation in patients with recurrent glioblastoma, while Part 2 will assess progression-free survival in newly diagnosed patients. The first site is University Hospitals Birmingham NHS Foundation Trust.
In April 2026, CRISM reported preclinical data for its prostate cancer programme showing a 58% reduction in tumour Volume compared with standard-of-care docetaxel. On the regulatory front, irinotecan-ChemoSeed holds Orphan Drug designation from the US Food and Drug Administration, and the company has an Innovation Passport from the UK medicines regulator. Patents have been granted in the EU and Japan, with applications progressing elsewhere.
Board changes have also taken place. Charles Spicer became non-executive chair on 1 October 2026, succeeding Nermeen Varawalla, who resigned in April 2026. The company held its Annual General Meeting on 27 October 2026, and announced an issue of new shares earlier that month.
Financial and Dividend picture
For the six months to 30 June 2026, CRISM reported a loss of £1.413m, up from £0.93m in the first half of 2025, as administrative expenses rose to £1.52m, mostly reflecting R&D. Cash stood at £2.269m at 30 June 2026, compared with £1.128m at the end of 2025, and the company reported net cash of £1.9m on 18 September 2026.
The improvement in cash followed a £2.745m placing and retail offer in May 2026, which included warrants exercisable at 15p until December 2027. The company has also secured grants from Innovate UK and Invest Northern Ireland totalling about £996,000. The directors said they had a reasonable expectation of adequate resources. As a pre-revenue biotech, CRISM does not pay a dividend.
Sector and index context
Glioblastoma remains one of the hardest cancers to treat, and approaches that deliver drugs directly to the tumour site have attracted scientific interest. Within the FTSE AIM All Share Index, CRISM is one of many small life sciences companies whose valuations depend heavily on clinical milestones and access to funding.
Key risks
Clinical trials can Fail or be delayed, and results from early-stage dose escalation may not predict later outcomes. The company's cash runway is modest relative to the cost of drug development, so further fundraising is likely, which could dilute shareholders. Reliance on a single trial site at present, regulatory requirements and competition from other therapies are further risks.
What to watch next
Key near-term milestones include confirmation that the first patient has been dosed, the addition of further trial sites and progress through the dose escalation stage. Investors will also watch for further non-dilutive funding and development of the prostate cancer programme during 2027.






Please wait processing your request...